title: Targeting JAK kinase in solid tumors: emerging opportunities and challenges.
abstract: Various human malignancies are characterized by excessive activation of the Janus family of cytoplasmic tyrosine kinases (JAK) and their associated transcription factors STAT3 and STAT5. In the majority of solid tumors, this occurs in response to increased abundance of inflammatory cytokines in the tumor microenvironment prominently produced by infiltrating innate immune cells. Many of these cytokines share common receptor subunits and belong to the interleukin (IL)-6/IL-11, IL-10/IL-22 and IL-12/IL-23 families. Therapeutic inhibition of the JAK/STAT3 pathway potentially offers considerable benefit owing to the capacity of JAK/STAT3 signaling to promote cancer hallmarks in the tumor and its environment, including proliferation, survival, angiogenesis, tumor metabolism while suppressing antitumor immunity. This is further emphasized by the current successful clinical applications of JAK-specific small molecule inhibitors for the treatment of inflammatory disorders and hematopoietic malignancies. Here we review current preclinical applications for JAK inhibitors for the treatment of solid cancers in mice, with a focus on the most common malignancies emanating from oncogenic transformation of the epithelial mucosa in the stomach and colon. Emerging data with small molecule JAK-specific adenosine triphosphate-binding analogs corroborate genetic findings and suggest that interference with the JAK/STAT3 pathway may suppress the growth of the most common forms of sporadic colon cancers that arise from mutations of the APC tumor suppressor gene. Likewise inhibition of cytokine-dependent activation of the JAK/STAT3 pathway may also afford orthogonal treatment opportunities for other oncogene-addicted cancer cells that have gained drug resistance.
authors.affiliation: Department of Medical Biology, Walter and Eliza Hall Institute, University of Melbourne, Melbourne, Victoria, Australia.|Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Austin Health, Heidelberg, Victoria, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Buchert
authors.affiliation: Department of Medical Biology, Walter and Eliza Hall Institute, University of Melbourne, Melbourne, Victoria, Australia.
authors.forename: C J
authors.initials: CJ
authors.lastname: Burns
authors.affiliation: Department of Medical Biology, Walter and Eliza Hall Institute, University of Melbourne, Melbourne, Victoria, Australia.|Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Austin Health, Heidelberg, Victoria, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Ernst
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D050796:STAT3 Transcription Factor / Q000378:metabolism; D050799:STAT5 Transcription Factor / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D050796:STAT3 Transcription Factor; D050799:STAT5 Transcription Factor; D053612:Janus Kinases